A prasugrel-based strategy is associated with a lower incidence of death, myocardial infarction (MI) or stroke than a ticagrelor-based strategy in patients with an acute coronary syndrome (ACS) with or without ST-segment elevation who are scheduled to undergo invasive evaluation. These findings come from the ISAR-REACT 5 trial, conducted in Germany and Italy, and were presented at the ESC Congress 2019. Patients assigned to ticagrelor (n = 2,012) received the loading dose as soon as possible after randomization; in the prasugrel group (n = 2,006), therapy was initiated as soon as possible after randomization in patients with ST-segment elevation but was postponed until after assessment of the coronary anatomy for those without ST-segment elevation. The rate of the primary end point (a composite of death, MI or stroke at 1 year) was 9.3% with ticagrelor and 6.9% with prasugrel (HR 1.36, 95% CI 1.09–1.70, P = 0.006). The lower incidence of the primary end point with prasugrel was driven by fewer MIs. The rate of major bleeding events was not significantly different between the groups.
References
Original article
Schüpke, S. et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1908973 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Ruiz, I. Prasugrel superior to ticagrelor in ACS. Nat Rev Cardiol 16, 646 (2019). https://doi.org/10.1038/s41569-019-0270-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0270-6